Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on May 30, 2013. The filing serves to disclose "Other Events" under Item 8.01, specifically the issuance of a press release dated May 30, 2013, which is attached as Exhibit 99.1. The registrant is incorporated in Delaware with principal executive offices in Annapolis, Maryland.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural report referencing an external press release and does not contain embedded financial statements or quantitative performance data.
Material Changes
No material financial changes versus a prior comparable period are detailed in the text of this filing. The report solely announces the release of a press statement.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, risks, or contingencies within the body of the 8-K. These details are presumed to be contained within the referenced press release (Exhibit 99.1), the text of which is not included in the provided input.
Key Facts for Investor Verification
- Verify the content of the press release dated May 30, 2013 (Exhibit 99.1) to understand the specific event triggering this filing.
- Confirm the company name is PharmAthene, Inc., as the input metadata incorrectly referenced Altimmune, Inc.
- Note that no financial data is present in this specific filing; investors must refer to the company's 10-K or 10-Q for financial metrics.